PDT Partners LLC maintained its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 52,769 shares of the company’s stock at the close of the 2nd quarter. PDT Partners LLC owned approximately 0.06% of IDEXX Laboratories worth $8,518,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of IDXX. D.A. Davidson & CO. raised its position in shares of IDEXX Laboratories by 160.4% during the 2nd quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after buying an additional 385 shares in the last quarter. Capital Advisors Ltd. LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $128,000. Global X Management Co. LLC raised its position in shares of IDEXX Laboratories by 44.6% during the 1st quarter. Global X Management Co. LLC now owns 1,047 shares of the company’s stock valued at $162,000 after buying an additional 323 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of IDEXX Laboratories during the 1st quarter valued at $200,000. Finally, Coastline Trust Co purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $202,000. Hedge funds and other institutional investors own 87.64% of the company’s stock.

IDXX has been the topic of several research reports. Zacks Investment Research cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, June 27th. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 target price on shares of IDEXX Laboratories in a report on Tuesday, June 13th. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a report on Monday, August 21st. BidaskClub raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Finally, CL King raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 target price on the stock in a report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $174.00.

TRADEMARK VIOLATION WARNING: “PDT Partners LLC Has $8,518,000 Holdings in IDEXX Laboratories, Inc. (IDXX)” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/pdt-partners-llc-has-8518000-holdings-in-idexx-laboratories-inc-idxx/1600942.html.

In other news, Director Lawrence D. Kingsley bought 2,000 shares of IDEXX Laboratories stock in a transaction dated Thursday, August 3rd. The shares were acquired at an average price of $151.76 per share, with a total value of $303,520.00. Following the completion of the purchase, the director now owns 3,344 shares in the company, valued at approximately $507,485.44. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Rebecca M. Henderson sold 2,578 shares of the stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $152.86, for a total transaction of $394,073.08. Following the completion of the sale, the director now directly owns 17,274 shares in the company, valued at approximately $2,640,503.64. The disclosure for this sale can be found here. In the last three months, insiders sold 151,734 shares of company stock worth $23,436,626. Insiders own 2.77% of the company’s stock.

Shares of IDEXX Laboratories, Inc. (IDXX) traded up 0.73% during midday trading on Friday, reaching $155.49. 392,762 shares of the company’s stock were exchanged. IDEXX Laboratories, Inc. has a 12-month low of $102.45 and a 12-month high of $173.01. The stock’s 50 day moving average is $154.86 and its 200-day moving average is $159.27. The stock has a market cap of $13.57 billion, a PE ratio of 53.49 and a beta of 0.49.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The business had revenue of $508.90 million for the quarter, compared to the consensus estimate of $502.44 million. During the same quarter in the prior year, the firm posted $0.74 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. On average, equities analysts expect that IDEXX Laboratories, Inc. will post $3.18 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.